Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,639,868

« Back to Dashboard

Details for Patent: 5,639,868

Title: High-affinity RNA ligands for basic fibroblast growth factor
Abstract:Methods are described for the identification and preparation of nucleic acid ligand solutions to basic fibroblast growth factor (bFGF). Included in the invention are nucleic acid ligands to bFGF which are inhibitors of bFGF and 2'-amino-modified RNA ligands to bFGF.
Inventor(s): Janjic; Nebojsa (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Feb 06, 1995
Application Number:08/384,708
Claims:1. A nucleic acid ligand to basic fibroblast growth factor (bFGF) identified according to the method comprising:

a) preparing a candidate mixture of nucleic acids;

b) contacting the candidate mixture with bFGF, wherein nucleic acids having an increased affinity to bFGF relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

c) partitioning the increased affinity nucleic acid ligands from the remainder of the candidate mixture; and

d) amplifying the increased affinity nucleic acid ligands for bFGF to yield a mixture of nucleic acids enriched for sequences with a higher affinity to bFGF, whereby a nucleic acid ligand of bFGF may be identified.

2. The nucleic acid ligand of claim 1 comprising a single stranded nucleic acid.

3. The nucleic acid ligand of claim 1 comprised of RNA.

4. The nucleic acid ligand of claim 3 comprised of RNA wherein all pyrimidines are 2'-deoxy-2'-NH.sub.2 pyrimidines.

5. A purified and isolated non-naturally occurring nucleic acid ligand to bFGF.

6. The nucleic acid ligand of claim 5 wherein said ligand is a RNA ligand.

7. The RNA ligand of claim 6 wherein said RNA ligand is selected from the group consisting of the nucleotide sequences set forth in FIGS. 4 and 5 and Tables IV and VIII, (SEQ ID NO:48-69 and SEQ ID NO:101-185, respectively).

8. The RNA ligand of claim 6 wherein said RNA ligand is an inhibitor of bFGF.

9. The nucleic acid ligand of claim 1 wherein the method of identifying further comprises

e) repeating steps b), c) and d).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.